APA (7th ed.) Citation

P, F., T, A., B, M., R, L., F, N., B, C., . . . S, L. (2018). Long-term follow up of the CLL2007FMP trial evaluating fludarabine and cyclophosphamide in combination with either rituximab or alemtuzumab in previously untreated patients with chronic lymphocytic leukemia. Haematologica, 103(7), e304. https://doi.org/10.3324/haematol.2017.183350

Chicago Style (17th ed.) Citation

P, Feugier, et al. "Long-term Follow Up of the CLL2007FMP Trial Evaluating Fludarabine and Cyclophosphamide in Combination with Either Rituximab or Alemtuzumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia." Haematologica 103, no. 7 (2018): e304. https://doi.org/10.3324/haematol.2017.183350.

MLA (9th ed.) Citation

P, Feugier, et al. "Long-term Follow Up of the CLL2007FMP Trial Evaluating Fludarabine and Cyclophosphamide in Combination with Either Rituximab or Alemtuzumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia." Haematologica, vol. 103, no. 7, 2018, p. e304, https://doi.org/10.3324/haematol.2017.183350.